Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection
Paulo R.L. Machado
, Alexsandro Lago, Thiago M. Cardoso, Andréa Magalhaes, Lucas P. Carvalho, Tainã Lago, Augusto M. Carvalho, Rúbia Costa, and Edgar M. Carvalho
Author affiliations: Federal University of Bahia, Salvador, Brazil (P.R.L. Machado, A. Lago, A. Magalhaes, L.P. Carvalho, T. Lago, R. Costa, E.M. Carvalho); National Institute of Science and Technology of Tropical Diseases (INCT-DT), Brasília, Brazil (P.R.L. Machado, L.P. Carvalho, A.M. Carvalho, E.M. Carvalho); Fiocruz, Salvador (T.M. Cardoso, A. Magalhaes, L.P. Carvalho, A.M. Carvalho, R. Costa, E.M. Carvalho)
Main Article
Figure 3
Figure 3. Kaplan-Meyer curve showing time to cure in the 2 groups of DL patients treated with meglumine antimoniate in monotherapy, Corte de Pedra Health Post, Brazil, 2016–2019. Patients with >50 lesions (n = 40) and <40 lesions (n = 55) were treated with meglumine antimoniate (20 mg/kg/d) for 20 days (p = 0.0012 by log-rank test). DL, disseminated leishmaniasis.
Main Article
Page created: January 26, 2024
Page updated: February 23, 2024
Page reviewed: February 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.